Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma : Myth or Reality?

© The Author(s) 2020..

BACKGROUND: Due to the relative rarity of small bowel adenocarcinoma (SBA), prospective trials, helping to guide therapeutic decisions, are lacking and the optimal therapy for advanced SBA is unknown. The role of targeted agents, such as anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor (VEGF), is unknown.

PATIENTS AND METHODS: This is a retrospective multicenter observational study that included patients with metastatic SBA treated with anti-EGFR antibodies (cetuximab or panitumumab) ± chemotherapy in the first (I) or second (II) line.

RESULTS: Thirteen patients with metastatic SBA, recruited from 5 Italian referral institutions, were included in the present retrospective analysis. All patients received anti-EGFR inhibitors as a single agent or in association with chemotherapy. More common G2 treatment-related side effects were skin reaction (8 patients, 53.8%), hypomagnesemia (6 patients, 46.2%), and diarrhea (8 patients, 61.5%). Grade 3 diarrhea was observed in only 1 patient. Conjunctivitis was not reported in any patients. Grade 4 toxicity was not reported. In the overall population, median progression-free survival was 5.526 months (95% confidence interval [CI]: 3.684-12.467). Median overall survival was 15.86 months (95% CI: 14.43-24.30). Complete response was observed in 15% of patients, partial response in 39% of patients, stable disease in 23% of patients, and progression disease in 15% of patients.

CONCLUSIONS: In this retrospective analysis, anti-EGFR inhibitors showed to be a suitable addendum to chemotherapy in the I and II line, with an excellent tolerance and safety profile both in I and II line.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:14

Enthalten in:

Clinical Medicine Insights. Oncology - 14(2020) vom: 28., Seite 1179554920946693

Sprache:

Englisch

Beteiligte Personen:

Dell'Aquila, Emanuela [VerfasserIn]
Zeppola, Tea [VerfasserIn]
Stellato, Marco [VerfasserIn]
Pantano, Francesco [VerfasserIn]
Scartozzi, Mario [VerfasserIn]
Madaudo, Cristina [VerfasserIn]
Pietrantonio, Filippo [VerfasserIn]
Cremolini, Chiara [VerfasserIn]
Aprile, Giuseppe [VerfasserIn]
Vincenzi, Bruno [VerfasserIn]
Moretto, Roberto [VerfasserIn]
Puzzoni, Marco [VerfasserIn]
Garattini, Silvio Ken [VerfasserIn]
Lobefaro, Riccardo [VerfasserIn]
Tonini, Giuseppe [VerfasserIn]
Santini, Daniele [VerfasserIn]

Links:

Volltext

Themen:

Anti-EGFR inhibitors
Cetuximab
Chemotherapy
Journal Article
Panitumumab
Small bowel adenocarcinoma
Toxicity

Anmerkungen:

Date Revised 16.04.2022

published: Electronic-eCollection

Citation Status PubMed-not-MEDLINE

doi:

10.1177/1179554920946693

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM313949182